bioAffinity Technologies, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $6.2M | $9.4M | $7.9M | $6.9M |
| Cost of Revenue | — | — | — | $467 |
| Gross Profit | — | — | — | $4.3K |
| Gross Margin | — | — | — | 0.1% |
| Operating Expenses | ||||
| Research & Development | $1.4M | $1.5M | $1.5M | $1.4M |
| SG&A Expense | $9.9M | $9.9M | $6.8M | $2.5M |
| Operating Income | $-10.6M | $-9.0M | $-8.0M | $-4.0M |
| Operating Margin | -171.6% | -95.6% | -100.9% | -58.1% |
| Interest Expense | — | — | $37.1K | $2.5M |
| Pretax Income | $-14.9M | $-9.0M | $-7.9M | $-8.2M |
| Income Tax Expense | $44.0K | $11.7K | $21.0K | $2.5K |
| Net Income | $-14.9M | $-9.0M | $-7.9M | $-8.2M |
| Net Margin | -242.0% | -96.6% | -100.5% | -118.2% |
| EPS (Basic) | $-8.66 | $-5.63 | $-0.23 | $-0.45 |
| EPS (Diluted) | $-8.66 | $-5.63 | $-0.23 | $-0.45 |
| Shares Outstanding (Basic) | 1.7M | 1.6M | 35.0M | 18.0M |
| Shares Outstanding (Diluted) | 1.7M | 1.6M | 35.0M | 18.0M |
| Dividends Per Share | — | — | — | — |